NRSN
NeuroSense Therapeutics Ltd.NASDAQHealthcare$0.83-8.19%ClosedMarket Cap: $20.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-12.41
P/S
0.00
EV/EBITDA
-2.92
DCF Value
$-0.03
FCF Yield
-0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
173600.0%
ROA
-633.3%
ROIC
465.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2025 | $0.00 | NaN% | $-2.3M | $-2.4M | $-0.09 | — |
| Q1 2025 | $0.00 | NaN% | $-2.3M | $-2.4M | $-0.09 | — |
| Q4 2024 | $0.00 | NaN% | $-1.8M | $-1.8M | $-0.08 | — |
| FY 2024 | $0.00 | NaN% | $-9.9M | $-10.2M | $-0.55 | — |
| Q3 2024 | $0.00 | NaN% | $-2.1M | $-2.1M | $-0.11 | — |
| Q2 2024 | $0.00 | NaN% | $-3.0M | $-857.0K | $-0.05 | — |
| Q1 2024 | $0.00 | NaN% | $-3.0M | $-5.4M | $-0.35 | — |
| Q4 2023 | $0.00 | NaN% | $-3.3M | $-3.0M | $-0.19 | — |
| FY 2023 | $0.00 | NaN% | $-12.0M | $-10.1M | $-0.83 | — |
| Q3 2023 | $0.00 | NaN% | $-2.9M | $784.0K | $0.06 | — |
| Q2 2023 | $0.00 | NaN% | $-3.5M | $-5.2M | $-0.38 | — |
| Q1 2023 | $0.00 | NaN% | $-3.0M | $-2.9M | $-0.25 | — |